Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

<p>Flow cytometry–based cytotoxicity assay. Determination of Dato-DXd and control ADC IC<sub>50</sub> (mean SEM) in the tested cell lines. <b>A,</b> Cell line with 0 TROP2 expression [i.e., END(K)34] showed no difference in the IC<sub>50</sub> of Dato-DXd an...

Full description

Saved in:
Bibliographic Details
Main Author: Niccolò G. Santin (22229756) (author)
Other Authors: Namrata Sethi (21290758) (author), Stefania Bellone (15122334) (author), Cem Demirkiran (17533603) (author), Victoria M. Ettorre (21290752) (author), Michelle Greenman (18472858) (author), Blair McNamara (17533585) (author), Natalia Buza (17533594) (author), Tobias M.P. Hartwich (15122337) (author), Luca Palmieri (22229759) (author), Domenica Lorusso (22229762) (author), Alessandro D. Santin (15122349) (author)
Published: 2025
Subjects:
Cancer
Cancer Detection and Diagnosis
Therapeutic Research and Development
Biological Agents & Therapies
Biomarkers
Drug Targets
Gynecological Cancers
Endometrial cancer
Prognostic Biomarkers
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items